Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data

Highlights • Suvorexant is a first-in-class orexin receptor antagonist for treating insomnia. • Sleep architecture is preserved in insomnia patients taking suvorexant. • The power spectral profile of suvorexant is similar to placebo.

Saved in:
Bibliographic Details
Published inSleep medicine Vol. 19; pp. 93 - 100
Main Authors Snyder, Ellen, Ma, Junshui, Svetnik, Vladimir, Connor, Kathryn M, Lines, Christopher, Michelson, David, Herring, W. Joseph
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.03.2016
Subjects
Azepines - therapeutic use
Electroencephalography - drug effects
Female
Humans
Male
Middle Aged
Neurology
Orexin
Orexin Receptor Antagonists - therapeutic use
Polysomnography
Polysomnography - drug effects
Power spectral density
Randomized Controlled Trials as Topic
Sleep architecture
Sleep Initiation and Maintenance Disorders - drug therapy
Sleep Medicine
Sleep Stages - drug effects
Suvorexant
Triazoles - therapeutic use
Power spectral density
Suvorexant
Sleep architecture
Polysomnography
Orexin
Online AccessGet full text

Cover

More Information
Summary:Highlights • Suvorexant is a first-in-class orexin receptor antagonist for treating insomnia. • Sleep architecture is preserved in insomnia patients taking suvorexant. • The power spectral profile of suvorexant is similar to placebo.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
ISSN:1389-9457
1878-5506
DOI:10.1016/j.sleep.2015.10.007